Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: Importance of accurate CT interpretation by experts

Abstract

Introduction: This study evaluated the clinical outcomes of stereotactic body radiotherapy (SBRT) for both pathologically diagnosed (PD) and clinically diagnosed (CD) early-stage non-small cell lung cancer (NSCLC) and explored the significance of accurate expert computed tomography (CT) interpretation.

Methods: We retrospectively analyzed 95 patients with early-stage NSCLC who received SBRT at our institution. Patients were classified into CD and PD groups. Two chest radiologists retrospectively interpreted the pre-SBRT CT images to determine the tumor subtype and probability of malignancy (PM). Clinical findings, CT features, and treatment outcomes were compared between the two groups. The survival rate of the CD group was analyzed separately according to the PM grade.

Results: Median overall survival for the CD and PD groups was 6.0 and 5.4 years (P = 0.57), respectively. Median cause-specific survival was 10.2 years in the CD group and not reached in the PD group (P = 0.76). In the CD group, lung cancer mortality was lower in the low PM group (25% [1 of 4]) than in the high PM group (47.4% [9 of 19]).

Conclusion: It may be desirable to evaluate the PM of the nodule using expert CT interpretation to decide whether SBRT is indicated in CD early-stage NSCLC.

Keywords

lung neopasms / oncologic imaging / radiation oncology imaging

References

[1] SebastianNT, Merritt RE, Abdel-RasoulM, et al. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2020;110(3):998-1005.

[2] BeiY, Murakami N, NakayamaY, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment. J Radiat Res. 2020;61(4):586-593.

[3] SchneiderBJ, DalyME, KennedyEB, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018;36(7):710-719.

[4] NakajoM, Jinguji M, AokiM, TaniA, SatoM, YoshiuraT. The clinical value of texture analysis of dual-time-point (18)F-FDG-PET/CT imaging to differentiate between (18)F-FDG-avid benign and malignant pulmonary lesions. Eur Radiol. 2020;30(3):1759-1769.

[5] BermanAT, Jabbour SK, VachaniA, et al. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res. 2019;8(1):5-14.

[6] ShaikhT, Churilla TM, MurphyCT, et al. Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer. 2016;11(7):1112-1120.

[7] DautrucheA, FilionE, MathieuD, et al. To Biopsy or Not to Biopsy?: A Matched Cohort Analysis of Early-Stage Lung Cancer Treated with Stereotactic Radiation with or Without Histologic Confirmation. Int J Radiat Oncol Biol Phys. 2020;107(1):88-97.

[8] MAIJ, ShoniM, SiegertC, et al. Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer. 2019;14(4):583-595.

[9] BaumannP, NymanJ, HoyerM, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290-3296.

[10] HaidarYM, RahnDA, 3rd, NathS, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014;8(1):3-12.

[11] LagerwaardFJ, Verstegen NE, HaasbeekCJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348-353.

[12] RosenLR, Fischer-Valuck BW, KatzSR, et al. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center. Tumori. 2014;100(1):42-48.

[13] CharlsonME, PompeiP, AlesKL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.

[14] NakataM, SaekiH, TakataI, et al. Focal ground-glass opacity detected by low-dose helical CT. Chest. 2002;121(5):1464-1467.

[15] KinoshitaF, Toyokawa G, MatsubaraT, et al. Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. Anticancer Res. 2019;39(5):2665-2670.

[16] IwanoS, Umakoshi H, KamiyaS, et al. Postoperative recurrence of clinical early-stage non-small cell lung cancers: a comparison between solid and subsolid nodules. Cancer Imaging. 2019;19(1):33.

[17] MiyazakiT, Yamazaki T, NakamuraD, et al. Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis. Surg Today. 2017;47(12):1476-1483.

[18] ChangJY, MehranRJ, FengL, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448-1457.

[19] PaulS, LeePC, MaoJ, IsaacsAJ, SedrakyanA. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570.

[20] KawaiH, TadaA, KawaharaM, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer–a multicenter study. Lung Cancer. 2005;49(1):63-70.

[21] RoachMC, RehmanS, DeWeesTA, Abraham CD, BradleyJD, RobinsonCG. It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. Pract Radiat Oncol. 2016;6(1):12-18.

[22] TimmermanRD, HuC, MichalskiJM, et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(9):1287-1288.

[23] MatsuoY, Takayama K, NagataY, et al. Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2007;68(2):416-425.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.